Latest news with #JasonWittes
Business Insider
09-08-2025
- Business
- Business Insider
Analysts' Top Healthcare Picks: Stereotaxis (STXS), Tectonic Therapeutic (TECX)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Stereotaxis (STXS – Research Report) and Tectonic Therapeutic (TECX – Research Report) with bullish sentiments. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Stereotaxis (STXS) Roth MKM analyst Jason Wittes reiterated a Buy rating on Stereotaxis today and set a price target of $5.00. The company's shares closed last Friday at $2.51. According to Wittes is a 4-star analyst with an average return of 4.3% and a 49.1% success rate. Wittes covers the Healthcare sector, focusing on stocks such as TriSalus Life Sciences, Zimmer Biomet Holdings, and Allurion Technologies. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Stereotaxis with a $4.50 average price target, which is a 95.7% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $5.00 price target. Tectonic Therapeutic (TECX) In a report released today, Uy Ear from Mizuho Securities reiterated a Buy rating on Tectonic Therapeutic, with a price target of $85.00. The company's shares closed last Friday at $22.00. According to Ear has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -6.0% and a 34.1% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Cartesian Therapeutics, and ACADIA Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tectonic Therapeutic with a $81.50 average price target, which is a 288.1% upside from current levels. In a report issued on August 6, Leerink Partners also maintained a Buy rating on the stock.
Business Insider
13-05-2025
- Business
- Business Insider
Roth MKM Sticks to Its Buy Rating for Stereotaxis (STXS)
In a report released yesterday, Jason Wittes from Roth MKM reiterated a Buy rating on Stereotaxis (STXS – Research Report), with a price target of $5.00. The company's shares closed yesterday at $2.07. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Wittes covers the Healthcare sector, focusing on stocks such as Globus Medical, Allurion Technologies, and Monogram Orthopaedics Inc. According to TipRanks, Wittes has an average return of 2.7% and a 48.06% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Stereotaxis with a $4.67 average price target, which is a 125.60% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $5.00 price target. STXS market cap is currently $183.1M and has a P/E ratio of -7.17. Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of STXS in relation to earlier this year. Most recently, in March 2025, Isaac Paul J , a Director at STXS bought 38,000.00 shares for a total of $68,780.00.
Business Insider
03-05-2025
- Business
- Business Insider
Lemaitre Vascular (LMAT) Receives a Buy from Roth MKM
In a report released today, Jason Wittes from Roth MKM maintained a Buy rating on Lemaitre Vascular (LMAT – Research Report), with a price target of $106.00. The company's shares closed today at $78.70. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Wittes is a 3-star analyst with an average return of 2.3% and a 46.18% success rate. Wittes covers the Healthcare sector, focusing on stocks such as Accuray, Globus Medical, and Allurion Technologies. Lemaitre Vascular has an analyst consensus of Moderate Buy, with a price target consensus of $107.29, implying a 36.33% upside from current levels. In a report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $115.00 price target. The company has a one-year high of $109.58 and a one-year low of $69.82. Currently, Lemaitre Vascular has an average volume of 225.9K. Based on the recent corporate insider activity of 74 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LMAT in relation to earlier this year. Most recently, in March 2025, Trent Kamke, the Senior V. P., Operations of LMAT sold 6,529.00 shares for a total of $525,015.67.
